New personalized treatment options for cancer

December 18, 2011

A new cancer research centre established at the University of Adelaide will focus on treatment options tailored to the individual, taking into account DNA and genetic variations between people.

The Centre for Personalised Cancer Medicine brings together a team of world-leading researchers with strengths in blood cancers and solid tumours, particularly breast, lung, sarcomas and melanoma.

Headed by Professor David Callen, the team will use tumour profiling and animal and cellular models to develop new drugs that target particular molecular changes in individual cancer patients.

"This centre reflects the trend towards a new, individualised approach to cancer medicine, taking into account genetic variations between people and their reaction to specific drugs," Professor Callen says.

"We will focus on improving the outcomes for cancer patients at all levels, from prevention through to treatment, survival, rehabilitation and palliative care, exploring novel and innovative approaches to cancer research.

"The big thrust at the moment is DNA sequencing. While it is still in the developmental stage, there are enormous resources being poured into this overseas and it looks like we will follow this lead in Australia."

The centre is already making headway in some areas, particularly in the treatment of sarcomas − rare malignant tumours which disproportionately affect young people and have a high mortality rate.

Dr Paul Neilsen, who oversees the Sarcoma Research Group, is collaborating with Royal Adelaide Hospital surgeon A/Prof Susan Neuhaus to trial new drugs on individual patient's tumours in a laboratory setting. "Currently these patients are treated with chemotherapy and radiotherapy but their outcomes are very poor and have not improved in the past decade," Dr Neilsen says.

"We have identified weak points in these tumours and are targeting them with new agents. The next step is to support pre-clinical trials in Australia."

Dr Neilsen lost his 18-year-old brother to Ewing's Sarcoma - a malignant bone tumour which occurs most frequently in male teenagers and has a mortality rate of 40%, but increases to 90% for metastatic or recurrent disease.

Adelaide man John Marshall was a lot older - 41 years of age - when he was diagnosed with Ewing's Sarcoma in July 2010, undergoing surgery to remove the tumour, along with 12 months of chemotherapy.

"The diagnosis floored me. I was a fit, happy, healthy guy who had never smoked, ate a healthy diet and worked out regularly. How could this happen to me?"

While Mr Marshall has been given the all clear following his treatment, he is keen to support sarcoma research being undertaken at the Centre for Cancer Personalised Medicine and the Royal Adelaide Hospital. He is planning a sponsored cycle ride through the French Alps in September 2102.
-end-
For more information on the new Centre go to www.adelaide.edu.au/cpcm/

University of Adelaide

Related Cancer Research Articles from Brightsurf:

As cancer has evolved, it is time for cancer research to do the same
Marking Lung Cancer Awareness month, a new study investigates the extent to which human-based, non-animal approaches are supplanting animal models in cancer research - comparing number of publications, funding, and publications associated with clinical trials between xenograft models and human organoids.

New liver cancer research targets non-cancer cells to blunt tumor growth
'Senotherapy,' a treatment that uses small molecule drugs to target ''senescent'' cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.

Blueprint to beat cancer launched today by World Cancer Research Fund (WCRF)
Overweight and obesity increase cancer risk. A new report published today by World Cancer Research Fund (WCRF), and presented at the European Congress on Obesity in Vienna, shows that overweight or obesity is a cause of at least 12 cancers, five more than WCRF findings a decade ago.

Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.

UA Cancer Center research team explores anti-breast cancer properties of soy
Genistein, a major compound in soy foods, might aid in the proper functioning of a gene that can malfunction to cause breast cancer.

Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.

The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.

Cancer Research UK announces Grand Challenge teams to answer biggest questions in cancer
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.

Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.

Leading cancer research organizations to host cancer immunotherapy conference
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.

Read More: Cancer Research News and Cancer Research Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.